Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CPRX
stocks logo

CPRX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
141.49M
-0.23%
0.308
-30%
142.40M
+0.69%
0.370
-17.78%
149.59M
+2.06%
0.400
-2.44%
Estimates Revision
The market is revising Upward the revenue expectations for Catalyst Pharmaceuticals, Inc. (CPRX) for FY2025, with the revenue forecasts being adjusted by 2.88% over the past three months. During the same period, the stock price has changed by 13.75%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.88%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+8.38%
In Past 3 Month
Stock Price
Go Up
up Image
+13.75%
In Past 3 Month
Wall Street analysts forecast CPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CPRX is 34.00 USD with a low forecast of 33.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast CPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CPRX is 34.00 USD with a low forecast of 33.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 23.080
sliders
Low
33.00
Averages
34.00
High
35.00
Current: 23.080
sliders
Low
33.00
Averages
34.00
High
35.00
Oppenheimer
Leland Gershell
Outperform
maintain
$32 -> $33
2025-11-07
Reason
Oppenheimer
Leland Gershell
Price Target
$32 -> $33
2025-11-07
maintain
Outperform
Reason
Oppenheimer analyst Leland Gershell raised the firm's price target on Catalyst Pharmaceuticals to $33 from $32 and keeps an Outperform rating on the shares. The firm notes the company reported Q3 total revenue of $148.4M, coming in well above its/consensus estimates of $136M/$137M and driving non-GAAP net income of $86.1M.
Citi
Buy
maintain
$31 -> $33
2025-11-07
Reason
Citi
Price Target
$31 -> $33
2025-11-07
maintain
Buy
Reason
Citi raised the firm's price target on Catalyst Pharmaceuticals to $33 from $31 and keeps a Buy rating on the shares. The firm sees the upper end of the company's 2025 outlook as potentially achievable following the Q3 report.
Baird
Joel Beatty
Buy
Maintains
$28 → $32
2025-03-03
Reason
Baird
Joel Beatty
Price Target
$28 → $32
2025-03-03
Maintains
Buy
Reason
Baird raised the firm's price target on Catalyst Pharmaceuticals to $32 from $28 and keeps an Outperform rating on the shares. The firm updated its model following its Q4 report as its Firdapse and Agamree are poised for a strong 2025.
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$35
2025-02-28
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$35
2025-02-28
Reiterates
Strong Buy
Reason
Stephens & Co.
Sudan Loganathan
Buy
Reiterates
$33
2025-02-27
Reason
Stephens & Co.
Sudan Loganathan
Price Target
$33
2025-02-27
Reiterates
Buy
Reason
Baird
Joel Beatty
Buy
Initiates
$28
2025-02-04
Reason
Baird
Joel Beatty
Price Target
$28
2025-02-04
Initiates
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Catalyst Pharmaceuticals Inc (CPRX.O) is 15.31, compared to its 5-year average forward P/E of 14.12. For a more detailed relative valuation and DCF analysis to assess Catalyst Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
14.12
Current PE
15.31
Overvalued PE
18.41
Undervalued PE
9.84

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
3.32
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
7.68
Undervalued EV/EBITDA
-1.04

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.09
Current PS
0.00
Overvalued PS
4.91
Undervalued PS
3.27
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CPRX News & Events

Events Timeline

(ET)
2025-11-05
17:41:44
Catalyst Pharmaceuticals Announces Q3 Earnings Per Share of 68 Cents, Exceeding Consensus Estimate of 54 Cents
select
2025-10-01 (ET)
2025-10-01
08:19:27
Catalyst Pharmaceuticals unveils $200 million stock buyback initiative
select
2025-08-25 (ET)
2025-08-25
08:14:43
Catalyst Pharmaceuticals reveals resolution of FIRDAPSE patent lawsuit
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.5
11-19Newsfilter
Catalyst Pharmaceuticals Named Among North America's Rapidly Expanding Companies in the 2025 Deloitte Technology Fast 500™

  • Catalyst Pharmaceuticals Recognition: Catalyst Pharmaceuticals ranked 304 on the 2025 Deloitte Technology Fast 500, achieving a 249% revenue growth from 2021 to 2024, marking its second consecutive year on the list.

  • Leadership and Growth Strategy: CEO Rich Daly attributes the company's success to its strong product portfolio and commercial capabilities, emphasizing a commitment to sustainable growth and patient care.

[object Object]
Preview
1.0
11-18Newsfilter
Catalyst Pharmaceuticals to Join Citi's 2025 Global Healthcare Conference

  • Company Announcement: Catalyst Pharmaceuticals, Inc. will participate in Citi's 2025 Global Healthcare Conference on December 2, 2025, with a presentation by President and CEO Rich Daly and the management team.

  • Webcast Availability: The presentation will be available via webcast on the company's website, with a replay accessible for at least 30 days.

  • Company Overview: Catalyst Pharmaceuticals focuses on developing and commercializing treatments for rare diseases, emphasizing patient care and accessibility, and has been recognized for its growth and success in the biopharmaceutical sector.

  • Forward-Looking Statements: The press release includes forward-looking statements that involve risks and uncertainties, with potential impacts on the company's future results, as detailed in their SEC filings.

[object Object]
Preview
7.0
11-07SeekingAlpha
Catalyst increases 2025 revenue forecast to $565M–$585M and announces $200M share repurchase initiative.

  • Management Performance: Catalyst Pharmaceuticals reported strong Q3 2025 results with total revenue of $148.4 million, a 15.3% year-over-year increase, driven by FIRDAPSE and AGAMREE, alongside a new $200 million share buyback program.

  • Revenue Guidance: The company raised its 2025 total revenue guidance to between $565 million and $585 million, with specific increases for FIRDAPSE, AGAMREE, and FYCOMPA, reflecting confidence in continued growth.

  • Financial Results: Q3 2025 net income was $52.8 million, with significant revenue contributions from FIRDAPSE ($92.2 million), AGAMREE ($32.4 million), and FYCOMPA ($23.8 million), while maintaining a strong cash position of $689.9 million.

  • Risks and Concerns: Management acknowledged risks from generic competition affecting FYCOMPA and ongoing patent litigation for FIRDAPSE, while analysts expressed concerns about sustaining growth amidst these challenges.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Catalyst Pharmaceuticals Inc (CPRX) stock price today?

The current price of CPRX is 23.08 USD — it has decreased -0.09 % in the last trading day.

arrow icon

What is Catalyst Pharmaceuticals Inc (CPRX)'s business?

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.

arrow icon

What is the price predicton of CPRX Stock?

Wall Street analysts forecast CPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CPRX is 34.00 USD with a low forecast of 33.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Catalyst Pharmaceuticals Inc (CPRX)'s revenue for the last quarter?

Catalyst Pharmaceuticals Inc revenue for the last quarter amounts to 148.39M USD, increased 15.31 % YoY.

arrow icon

What is Catalyst Pharmaceuticals Inc (CPRX)'s earnings per share (EPS) for the last quarter?

Catalyst Pharmaceuticals Inc. EPS for the last quarter amounts to 0.42 USD, increased 20.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Catalyst Pharmaceuticals Inc (CPRX)'s fundamentals?

The market is revising Upward the revenue expectations for Catalyst Pharmaceuticals, Inc. (CPRX) for FY2025, with the revenue forecasts being adjusted by 2.88% over the past three months. During the same period, the stock price has changed by 13.75%.
arrow icon

How many employees does Catalyst Pharmaceuticals Inc (CPRX). have?

Catalyst Pharmaceuticals Inc (CPRX) has 181 emplpoyees as of December 05 2025.

arrow icon

What is Catalyst Pharmaceuticals Inc (CPRX) market cap?

Today CPRX has the market capitalization of 2.84B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free